Opinion: Part B's high drug costs will hurt taxpayers, seniors

07/9/2013 | Forbes

The growth of Part B drug spending, which reached $19.5 billion in 2010, should decelerate this year, John S. Wilson writes. Medicare will continue to spend more for less because of what he calls excessive drug patent protections and poor pricing practices of the CMS, and that hurts seniors and taxpayers, he writes.

View Full Article in: